Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia : a CLCG-EORTC reportVILMER, E; SUCIU, S; MANEL, A.-M et al.Leukemia. 2000, Vol 14, Num 12, pp 2257-2266, issn 0887-6924Article

Pentostatin (nipent) in T-cell malignanciesHO, A. D; SUCIU, S; ZITTOUN, R et al.Seminars in oncology. 2000, Vol 27, Num 2, pp 52-57, issn 0093-7754, SUP5Conference Paper

Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemias (AML) in first remission. An EORTC/Gimema phase III trial (AML8 B)ZITTOUN, R; LISO, V; SOLBU, G et al.Leukemia. 1992, Vol 6, pp 76-77, issn 0887-6924, SUP2Conference Paper

Alternating ν repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC leukemia cooperative groupZITTOUN, R; JEHN, U; SUCIU, S et al.Blood. 1989, Vol 73, Num 4, pp 896-906, issn 0006-4971Article

A randomized comparison of maintenance treatment with androgens, immunotherapy in adult acute myelogenous leukemia: a leukemia-lymphoma group trial of the EORTCHAYAT, M; JEHN, U; KERKHOFS, H et al.Cancer. 1986, Vol 58, Num 3, pp 617-623, issn 0008-543XArticle

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy : A cross-sectional study of the EORTC-GIMENA AML 8A trialZITTOUN, R; SUCIU, S; DARDENNE, M et al.Bone marrow transplantation (Basingstoke). 1997, Vol 20, Num 4, pp 307-315, issn 0268-3369Article

Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin : A phase-II study (no. 06901) of the EORTC Leukemia Cooperative GroupDE WITTE, T; SUCIU, S; SOLBU, G et al.Annals of hematology (Print). 1996, Vol 72, Num 3, pp 119-124, issn 0939-5555Article

Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasmsHO, A. D; THALER, J; SUCIU, S et al.Cancer treatment reviews. 1990, Vol 17, Num 2-3, pp 213-215, issn 0305-7372, 3 p.Article

Pentostatin in refractory chronic lymphocytic leukemia : a phase II trial of the european organization for research and treatment of cancerHO, A. D; THALER, J; DE WITTE, T et al.Journal of the National Cancer Institute. 1990, Vol 82, Num 17, pp 1416-1420, issn 0027-8874Article

Prognostic value of cytologic parameters acute myelogenous leukemia = Valeur pronostique des paramètres cytologiques de la leucémie myélocytaire aiguëZITTOUN, R; CADIOU, M; BAYLE, C et al.Cancer. 1984, Vol 53, Num 7, pp 1526-1532, issn 0008-543XArticle

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trialKEATING, S; SUCIU, S; VARET, B et al.Leukemia. 2003, Vol 17, Num 1, pp 60-67, issn 0887-6924, 8 p.Article

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy : The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly : Final report of the leukemia cooperative group of the european organization for the research and treatment of cancer and the Dutch-Belgian hemato-oncology cooperative hovon group randomized phase III study AML-9LÖWENBERG, B; SUCIU, S; SONNEVELD, P et al.Journal of clinical oncology. 1998, Vol 16, Num 3, pp 872-881, issn 0732-183XArticle

Autologus or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemiaZITTOUN, R. A; MANDELLI, F; CARONIA, F et al.The New England journal of medicine. 1995, Vol 332, Num 4, pp 217-223, issn 0028-4793Article

A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemiaGERHARTZ, H. H; MARCUS, R; FIERE, D et al.Leukemia. 1994, Vol 8, Num 1, pp 16-23, issn 0887-6924Article

Autologous bone marrow transplantation in acute malignant haemopathologies : autologous malignant haemopathologies : autologous bone marrow transplantation in acute leukemiaZITTOUN, R; RIO, B; GATTRINGER, C et al.Nouvelle revue française d'hématologie. 1993, Vol 35, Num 1, pp 15-16, issn 0029-4810Conference Paper

Therapy of adult ALL : overview of 2 successive EORTC studies : ALL-2 & ALL-3STRYCKMANS, P; DE WITTE, T; LABAR, B et al.Leukemia. 1992, Vol 6, pp 199-203, issn 0887-6924, SUP2Conference Paper

Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative pilot studyBOILLETOT, A; BEHAR, C; OTTEN, J et al.The American journal of pediatric hematology/oncology. 1987, Vol 9, Num 4, pp 317-323, issn 0192-8562Article

Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemiaTHYSS, A; SUCIU, S; LUTZ, P et al.Journal of clinical oncology. 1997, Vol 15, Num 5, pp 1824-1830, issn 0732-183XArticle

Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia : A pilot studyGERHARTZ, H. H; ZWIERZINA, H. H; WALTHER, J et al.Cancer investigation. 1996, Vol 14, Num 4, pp 299-306, issn 0735-7907Article

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia : A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative GroupZITTOUN, R; SUCIU, S; PETTI, M. C et al.Journal of clinical oncology. 1996, Vol 14, Num 7, pp 2150-2159, issn 0732-183XArticle

Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)DE WITTE, T; SUCIU, S; SOLBU, G et al.Leukemia. 1995, Vol 9, Num 11, pp 1805-1811, issn 0887-6924Article

Allogeneic versus autologous bone marrox transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A)ZITTOUN, R; MANDELLI, F; VEGNA, M. L et al.Leukemia. 1992, Vol 6, pp 114-115, issn 0887-6924, SUP2Conference Paper

A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy : AML-6 trial of the EORTC leukemia cooperative groupJEHN, U; ZITTOUN, R; SUCIU, S et al.Haematology and blood transfusion. 1990, Vol 33, pp 277-284, issn 0171-7111Article

Dutch childhood leukemia study group : early results of study ALL VI (1984-1988)VEERMAN, A. J. P; HAÊHLEN, K; KAMPS, W. A et al.Haematology and blood transfusion. 1990, Vol 33, pp 473-477, issn 0171-7111Article

Post remission treatment in acute myelogenous leukaemia in first remission. The EORTC experienceWILLEMZE, R; ZITTOUN, R; MANDELLI, F et al.Bone marrow transplantation (Basingstoke). 1989, Vol 4, issn 0268-3369, p. 72, suppl. 3Conference Paper